ABBOTT LABORATORIES acquires Solvay Pharmaceuticals

ABBOTT LABORATORIES acquired Solvay Pharmaceuticals for EUR 4.5 billion (approximately $6.2 billion) in cash, plus potential additional payments, a transaction completed in February 2010, structured as all cash.

Solvay Pharmaceuticals operates in Pharmaceuticals, is based in Brussels, Belgium (global, emerging-markets weighted). Solvay Pharmaceuticals is the pharmaceuticals business of the Solvay Group, with a diversified portfolio of branded specialty pharmaceutical products and a strong international, particularly emerging-markets, footprint.

Diversifies Abbott's pharmaceutical products and expands its international growth platform, supporting long-term strategic growth in emerging markets.

Diversified pharmaceutical portfolio with a strong emerging-markets growth platform. Integrated into Abbott's pharmaceutical products business

Advisory firms were not disclosed for this transaction.

You're subscribed.

Thanks for signing up.